Updated efficacy and safety of anti-BCMA CAR-T for the treatment of R/R AL amyloidosis

Feasibility of BCMA-directed CAR-T therapy in R/R AL amyloidosisПодробнее

Safety of HBI0101 (NXC-201), a novel academic anti-BCMA CAR-T, in R/R AL amyloidosisПодробнее

Safety & efficacy of cesnicabtagene autoleucel (ARI0002H) in R/R multiple myelomaПодробнее

The Promise of Anti-BCMA CAR T-Cell Therapy in MMПодробнее

Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020Подробнее

The impact of prior BCMA CAR-T therapy on the efficacy BCMA-targeting bispecifics in myelomaПодробнее

The promise of CAR-T therapy for the treatment of AL amyloidosisПодробнее

Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosisПодробнее

Results of a Phase I trial of HBI0101, an anti-BCMA CAR T-cell therapy, for R/R multiple myelomaПодробнее

PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myelomaПодробнее

Sequential CD19 and BCMA CAR-TПодробнее

Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in RR Multiple MyelomaПодробнее

BCMA-specific CAR-T cells for R/R multiple myelomaПодробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее

Efficacy and Safety of Elranatamab in Pts with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3Подробнее

Phase 1 Clinical Study of the BCMA Nex T CAR T Cell Therapy CC-98633/BMS-986354 in pts with RRMMПодробнее

Phase I/II trial of P-BCMA-101 CAR-T cell therapy in R/R myelomaПодробнее

Meta-analysis: anti-BCMA CAR-T in R/R multiple myelomaПодробнее

BCMA-CD38 bispecific CAR-T cells in R/R MMПодробнее